Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04939701
Title Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Astellas Pharma Global Development, Inc.

ovarian cancer

Advanced Solid Tumor

lung adenocarcinoma


esophagus squamous cell carcinoma

lung non-small cell carcinoma

lung squamous cell carcinoma

myxoid liposarcoma

synovial sarcoma


ASP0739 + Pembrolizumab


Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.